严重非变态反应性嗜酸性粒细胞性哮喘患者单剂量服用美宝珠单抗后血清上皮衍生细胞因子白细胞介素-25和胸腺基质淋巴结蛋白水平：一份简短报告。

IF 2.1 4区医学 Q3 RESPIRATORY SYSTEM

Canadian respiratory journal Pub Date : 2019-12-01 eCollection Date: 2019-01-01 DOI:10.1155/2019/8607657

Virginija Kalinauskaite-Zukauske, Andrius Januskevicius, Ieva Janulaityte, Skaidrius Miliauskas, Kestutis Malakauskas

{"title":"严重非变态反应性嗜酸性粒细胞性哮喘患者单剂量服用美宝珠单抗后血清上皮衍生细胞因子白细胞介素-25和胸腺基质淋巴结蛋白水平：一份简短报告。","authors":"Virginija Kalinauskaite-Zukauske, Andrius Januskevicius, Ieva Janulaityte, Skaidrius Miliauskas, Kestutis Malakauskas","doi":"10.1155/2019/8607657","DOIUrl":null,"url":null,"abstract":"The bronchial epithelium has continuous contact with environmental agents initiating and maintaining airway type 2 inflammation in asthma. However, there is a lack of data on whether reduced airway eosinophilic inflammation can affect the production of epithelial-derived mediators, such as interleukin-25 (IL-25) and thymic stromal lymphopoietin (TSLP). The aim of this study was to investigate the changes in serum levels of IL-25 and TSLP after a single dose of mepolizumab, a humanized monoclonal antibody to interleukin-5 (IL-5), in patients with severe non-allergic eosinophilic asthma (SNEA). We examined 9 SNEA patients before and four weeks after administration of 100 mg mepolizumab subcutaneously. The fractional exhaled nitric oxide (FeNO) level was analysed using an electrochemical assay (NIOX VERO®, Circassia, UK). Serum IL-25 and TSLP levels were measured by ELISA. Four weeks after the single dose of mepolizumab, blood eosinophil count significantly decreased from 0.55 ± 0.20 × 109/l to 0.14 ± 0.04 × 109/l (p = 0.01) and FEV1 increased from 2.1 ± 0.5 l (65.4 ± 8.8% of predicted) to 2.6 ± 0.4 l (76.4 ± 9.1% of predicted) (p = 0.04), while FeNO level has not changed (32.3 ± 8.4 vs 42.9 ± 12.6 ppb). Serum IL-25 level significantly decreased from 48.0 ± 17.2 pg/mL to 34.8 ± 17.1 pg/mL (p = 0.02) with same tendency in TSLP level: from 359.8 ± 71.3 pg/mL to 275.6 ± 47.8 pg/mL (p = 0.02). It has also been noticed a significant relation between changes in the blood eosinophil count and serum IL-25 level (r = 0.81, p = 0.008), as well as between changes in serum IL-25 and TSLP levels (r = 0.93, p = 0.004) after a single dose of mepolizumab. Thus, anti-IL-5 treatment with mepolizumab might diminish the production of bronchial epithelial-derived cytokines IL-25 and TSLP in patients with SNEA which is potentially related to reduced eosinophilic inflammation. This trial is registered in ClinicalTrial.gov with identifier NCT03388359.","PeriodicalId":9416,"journal":{"name":"Canadian respiratory journal","volume":"2019 ","pages":"8607657"},"PeriodicalIF":2.1000,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2019/8607657","citationCount":"13","resultStr":"{\"title\":\"Serum Levels of Epithelial-Derived Cytokines as Interleukin-25 and Thymic Stromal Lymphopoietin after a Single Dose of Mepolizumab in Patients with Severe Non-Allergic Eosinophilic Asthma: A Short Report.\",\"authors\":\"Virginija Kalinauskaite-Zukauske, Andrius Januskevicius, Ieva Janulaityte, Skaidrius Miliauskas, Kestutis Malakauskas\",\"doi\":\"10.1155/2019/8607657\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The bronchial epithelium has continuous contact with environmental agents initiating and maintaining airway type 2 inflammation in asthma. However, there is a lack of data on whether reduced airway eosinophilic inflammation can affect the production of epithelial-derived mediators, such as interleukin-25 (IL-25) and thymic stromal lymphopoietin (TSLP). The aim of this study was to investigate the changes in serum levels of IL-25 and TSLP after a single dose of mepolizumab, a humanized monoclonal antibody to interleukin-5 (IL-5), in patients with severe non-allergic eosinophilic asthma (SNEA). We examined 9 SNEA patients before and four weeks after administration of 100 mg mepolizumab subcutaneously. The fractional exhaled nitric oxide (FeNO) level was analysed using an electrochemical assay (NIOX VERO®, Circassia, UK). Serum IL-25 and TSLP levels were measured by ELISA. Four weeks after the single dose of mepolizumab, blood eosinophil count significantly decreased from 0.55 ± 0.20 × 109/l to 0.14 ± 0.04 × 109/l (p = 0.01) and FEV1 increased from 2.1 ± 0.5 l (65.4 ± 8.8% of predicted) to 2.6 ± 0.4 l (76.4 ± 9.1% of predicted) (p = 0.04), while FeNO level has not changed (32.3 ± 8.4 vs 42.9 ± 12.6 ppb). Serum IL-25 level significantly decreased from 48.0 ± 17.2 pg/mL to 34.8 ± 17.1 pg/mL (p = 0.02) with same tendency in TSLP level: from 359.8 ± 71.3 pg/mL to 275.6 ± 47.8 pg/mL (p = 0.02). It has also been noticed a significant relation between changes in the blood eosinophil count and serum IL-25 level (r = 0.81, p = 0.008), as well as between changes in serum IL-25 and TSLP levels (r = 0.93, p = 0.004) after a single dose of mepolizumab. Thus, anti-IL-5 treatment with mepolizumab might diminish the production of bronchial epithelial-derived cytokines IL-25 and TSLP in patients with SNEA which is potentially related to reduced eosinophilic inflammation. This trial is registered in ClinicalTrial.gov with identifier NCT03388359.\",\"PeriodicalId\":9416,\"journal\":{\"name\":\"Canadian respiratory journal\",\"volume\":\"2019 \",\"pages\":\"8607657\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2019-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1155/2019/8607657\",\"citationCount\":\"13\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Canadian respiratory journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1155/2019/8607657\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2019/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian respiratory journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2019/8607657","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 13

摘要

支气管上皮与环境因子持续接触，在哮喘中引发并维持气道2型炎症。然而，缺乏关于气道嗜酸性粒细胞炎症减少是否会影响上皮衍生介质的产生的数据，如白细胞介素-25（IL-25）和胸腺基质淋巴细胞生成素（TSLP）。本研究的目的是研究严重非过敏性嗜酸性粒细胞哮喘（SNEA）患者单剂量使用人源化白细胞介素-5单克隆抗体美波利珠单抗后血清中白细胞介质介素-5和TSLP水平的变化。我们在服用100 mg美波珠单抗皮下注射。使用电化学测定法（NIOX VERO®，Circasia，UK）分析呼出一氧化氮（FeNO）的分数水平。ELISA法测定血清IL-25和TSLP水平。单次服用美波珠单抗四周后，血液嗜酸性粒细胞计数从0.55显著下降 ± 0.20 × 109/l至0.14 ± 0.04 × 109/l（p=0.01），FEV1从2.1增加 ± 0.5 l（65.4 ± 预测的8.8%）至2.6 ± 0.4 l（76.4 ± 预测的9.1%）（p=0.04），而FeNO水平没有变化（32.3 ± 8.4对42.9 ± 12.6 ppb）。血清IL-25水平从48.0显著下降 ± 17.2 pg/mL至34.8 ± 17.1 pg/mL（p=0.02），TSLP水平有相同趋势：从359.8 ± 71.3 pg/mL至275.6 ± 47.8 pg/mL（p=0.02）。血嗜酸性粒细胞计数的变化与血清IL-25水平之间也存在显著关系（r = 0.81，p=0.008），以及血清IL-25和TSLP水平变化之间（r = 0.93，p=0.004）。因此，在SNEA患者中，用美波珠单抗进行抗IL-5治疗可能会减少支气管上皮衍生的细胞因子IL-25和TSLP的产生，这可能与减少嗜酸性粒细胞炎症有关。该试验在ClinicalTrial.gov注册，标识符为NCT03388359。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Serum Levels of Epithelial-Derived Cytokines as Interleukin-25 and Thymic Stromal Lymphopoietin after a Single Dose of Mepolizumab in Patients with Severe Non-Allergic Eosinophilic Asthma: A Short Report.

查看原文本刊更多论文

The bronchial epithelium has continuous contact with environmental agents initiating and maintaining airway type 2 inflammation in asthma. However, there is a lack of data on whether reduced airway eosinophilic inflammation can affect the production of epithelial-derived mediators, such as interleukin-25 (IL-25) and thymic stromal lymphopoietin (TSLP). The aim of this study was to investigate the changes in serum levels of IL-25 and TSLP after a single dose of mepolizumab, a humanized monoclonal antibody to interleukin-5 (IL-5), in patients with severe non-allergic eosinophilic asthma (SNEA). We examined 9 SNEA patients before and four weeks after administration of 100 mg mepolizumab subcutaneously. The fractional exhaled nitric oxide (FeNO) level was analysed using an electrochemical assay (NIOX VERO®, Circassia, UK). Serum IL-25 and TSLP levels were measured by ELISA. Four weeks after the single dose of mepolizumab, blood eosinophil count significantly decreased from 0.55 ± 0.20 × 10⁹/l to 0.14 ± 0.04 × 10⁹/l (p = 0.01) and FEV₁ increased from 2.1 ± 0.5 l (65.4 ± 8.8% of predicted) to 2.6 ± 0.4 l (76.4 ± 9.1% of predicted) (p = 0.04), while FeNO level has not changed (32.3 ± 8.4 vs 42.9 ± 12.6 ppb). Serum IL-25 level significantly decreased from 48.0 ± 17.2 pg/mL to 34.8 ± 17.1 pg/mL (p = 0.02) with same tendency in TSLP level: from 359.8 ± 71.3 pg/mL to 275.6 ± 47.8 pg/mL (p = 0.02). It has also been noticed a significant relation between changes in the blood eosinophil count and serum IL-25 level (r = 0.81, p = 0.008), as well as between changes in serum IL-25 and TSLP levels (r = 0.93, p = 0.004) after a single dose of mepolizumab. Thus, anti-IL-5 treatment with mepolizumab might diminish the production of bronchial epithelial-derived cytokines IL-25 and TSLP in patients with SNEA which is potentially related to reduced eosinophilic inflammation. This trial is registered in ClinicalTrial.gov with identifier NCT03388359.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Canadian respiratory journal 医学-呼吸系统

CiteScore

4.20

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Canadian Respiratory Journal is a peer-reviewed, Open Access journal that aims to provide a multidisciplinary forum for research in all areas of respiratory medicine. The journal publishes original research articles, review articles, and clinical studies related to asthma, allergy, COPD, non-invasive ventilation, therapeutic intervention, lung cancer, airway and lung infections, as well as any other respiratory diseases.